Deep brain stimulation boosts the strength of brain cell batteries
Research shows that deep brain stimulation may help boost energy levels in Parkinson’s brain cells by increasing the size of mitochondria.
Drug for dyskinesia approved for phase 2 trials
A potential drug for dyskinesia has reached an important milestone and can now go forward into clinical trials.
GDNF clinical trial offers hope for restoring brain cells damaged in Parkinson’s
The pioneering GDNF clinical trials programme delivered an experimental treatment directly to the brain. The trial results offer hope that it may be possible to restore the cells damaged in Parkinson’s.
Open publishing platform launched to share research results
Parkinson's UK is 1 of 24 members of the Association of Medical Research Charities that have worked in collaboration to develop and launch a new open publication platform – AMRC Open Research.
New trial to test if a probiotic drink could improve symptoms
Researchers at King’s College London are starting a world-first clinical trial to test if a probiotic drink could help with motor and non-motor symptoms of Parkinson's.
GDNF trial complete and results are on the way
The groundbreaking clinical trial of GDNF, a potential treatment for Parkinson's, is now complete. Analysis of the results is now well underway and is expected to be published in February 2019.
Insight Into Parkinson's summit 2019
Parkinson's UK announces partnership with the Insight Into Parkinson's summit 2019.
New research on levodopa's influence on Parkinson's progression
A clinical trial has produced further evidence that there is no benefit of delaying levodopa therapy.
Steps towards new drugs to improve symptoms and slow Parkinson’s
We’re investing a further £1.5million to advance pioneering drug discovery work to develop new molecules that can both improve symptoms and slow progression.
Scientists use gene editing to create 'tougher' stem cells
Researchers at the University of Edinburgh have used cutting-edge gene-editing techniques to create stem cells that are resistant to developing Parkinson’s.